Health Canada approves Ipsen and Medision Pharma’s Bylvay for pruritus treatment
Ipsen and Medision Pharma have announced that Health Canada has approved Bylvay (odevixibat) for the treatment of pruritis in patients aged six months or older with Progressive Familial Intrahepatic Cholestasis (PFIC). Bylvay is the first medication approved in Canada for this indication.
Both companies are part of a multiregional partnership in Canada and Israel in order to bring Bylvay to more patients with PFIC.
Gil Gurfinkle, CEO and Medision Pharma, commented: “At Medison, accelerating patients’ access to innovative treatments is leading all that we do, so we are pleased and proud to bring Bylvay to patients in Canada. We work hard, leveraging our multi-regional platform, to be the partner-of-choice for emerging biotech companies seeking to make their products available in international markets.”
Steward Campbell, executive vice president and president of North America, Ipsen, added: “Health Canada’s authorisation of Bylvay brings an important medicine to Canadians living with PFIC and their families. Bringing new medicines to new markets where unmet need exists illustrates Ipsen’s mission to improve patient lives. We are pleased to work with Medison to get Bylvay to prescribers as soon as possible.”
Alvotech and JAMP Pharma have announced that Health Canada has granted JAMP Pharma marketing authorisation …
Ipsen has announced that the US Food and Drug Administration (FDA) has approved Sohonos (palovarotene) …